The Institut Curie is a major player in the research and fight against cancer. It consists of a hospital and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Curie Institute Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient
This position is funded by an ERC Synergy program entitled “Kill or Differentiate“ which gathers scientists at Harvard, Karolinska and Curie. The project aims to identify signals/pathways that may convert neuroblastoma tumors to therapy-sensitive states. The main mission of the position will focus on the analysis of interactions between different cells populations (tumor cells, CAFs, immune cells…) and the definition of novel therapeutic approaches. The project will take advantage of the variety of cell and mouse models that are available in the group as well as data obtained on human samples using single-cell RNAseq.
- Experience level / degrees required
- Doctoral and/or postdoctoral experience.
- Skills and qualities required
- Strong interest for interdisciplinary research
- Broad expertise in biology as immunology, cell signalling, tumor microenvironment and imaging.
- In addition, s/he should be team players and have a strong affinity with working in an interdisciplinary and international research environment
- English required (oral and written skills) – French is optional
All our opportunities are open to people with disabilities
- Type of contrat : CDD
- Duration : 3 years
- Working time : full time.
- Advantage : Collective catering, reimbursement of transportation fees up to 70%, supplementary health insurance
The remuneration will follow the rules of the Research Center and will depend on the experience of the candidates
Applications (CV, motivation letter, letters from or contact details of 3 referees) to Dr Olivier Delattre: firstname.lastname@example.org and Isabelle Janoueix: Isabelle.email@example.com
Publication date : January 26th 2021
Deadline for applications : February 21st 2021